Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 12, 2026
DataAggregated Company Financials
Companies64
  • 7D-2.3%
  • 3M9.1%
  • 1Y7.3%
  • YTD-13.9%

The Life Sciences is pretty flat in the last 7 days, but Danaher has stood out, gaining 3.1%. As for the the longer term, the industry is up 8.1% over the past 12 months. Looking forward, earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 12 Jun 2026US$589.9bUS$150.6bUS$13.8b39.7x42.9x3.9x
Sun, 10 May 2026US$561.7bUS$150.3bUS$14.0b33x40.1x3.7x
Tue, 07 Apr 2026US$561.9bUS$147.8bUS$14.1b37.5x39.9x3.8x
Thu, 05 Mar 2026US$584.0bUS$147.8bUS$14.0b34.9x41.7x4x
Sat, 31 Jan 2026US$662.4bUS$147.0bUS$12.6b34x52.6x4.5x
Mon, 29 Dec 2025US$663.9bUS$145.8bUS$12.5b35.4x53.2x4.6x
Wed, 26 Nov 2025US$678.5bUS$145.6bUS$12.4b37.9x54.8x4.7x
Fri, 24 Oct 2025US$651.0bUS$145.2bUS$14.6b33.4x44.5x4.5x
Sun, 21 Sep 2025US$573.4bUS$144.3bUS$14.6b30.7x39.4x4x
Tue, 19 Aug 2025US$583.4bUS$144.2bUS$14.5b28.8x40.3x4x
Thu, 17 Jul 2025US$524.4bUS$142.9bUS$9.1b35.6x57.4x3.7x
Sat, 14 Jun 2025US$537.5bUS$142.9bUS$9.2b35.7x58.6x3.8x
Mon, 12 May 2025US$505.4bUS$142.8bUS$9.6b34.4x52.7x3.5x
Wed, 09 Apr 2025US$509.1bUS$142.5bUS$9.9b32x51.2x3.6x
Fri, 07 Mar 2025US$602.1bUS$143.1bUS$9.8b41.9x61.7x4.2x
Sun, 02 Feb 2025US$691.5bUS$143.0bUS$10.4b41.1x66.5x4.8x
Tue, 31 Dec 2024US$657.8bUS$142.4bUS$10.2b44.3x64.3x4.6x
Thu, 28 Nov 2024US$660.7bUS$142.4bUS$10.2b44.4x64.6x4.6x
Sat, 26 Oct 2024US$680.4bUS$142.0bUS$8.3b35.4x82.3x4.8x
Mon, 23 Sep 2024US$746.6bUS$141.8bUS$8.5b37.7x87.9x5.3x
Wed, 21 Aug 2024US$746.1bUS$141.9bUS$8.3b38.2x90x5.3x
Fri, 19 Jul 2024US$697.6bUS$141.2bUS$12.2b39.9x57.1x4.9x
Sun, 16 Jun 2024US$695.0bUS$141.3bUS$12.2b37.1x57.1x4.9x
Tue, 14 May 2024US$724.6bUS$141.5bUS$12.6b38.5x57.7x5.1x
Thu, 11 Apr 2024US$742.9bUS$142.0bUS$12.8b43.4x58.1x5.2x
Sat, 09 Mar 2024US$754.1bUS$142.1bUS$12.8b44.5x58.8x5.3x
Mon, 05 Feb 2024US$709.3bUS$147.5bUS$12.5b38.3x56.6x4.8x
Wed, 03 Jan 2024US$706.4bUS$153.9bUS$14.2b37.7x49.8x4.6x
Fri, 01 Dec 2023US$643.6bUS$153.8bUS$14.0b35x45.9x4.2x
Sun, 29 Oct 2023US$565.9bUS$153.8bUS$11.3b29.2x50.3x3.7x
Tue, 26 Sep 2023US$674.7bUS$154.6bUS$11.2b33.7x60.2x4.4x
Thu, 24 Aug 2023US$713.3bUS$154.6bUS$11.2b32.8x63.6x4.6x
Sat, 22 Jul 2023US$741.4bUS$155.5bUS$12.7b29.4x58.4x4.8x
Mon, 19 Jun 2023US$704.3bUS$152.4bUS$12.5b29.3x56.3x4.6x
Price to Earnings Ratio

56.3x


Total Market Cap: US$704.3bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 43.8x which is lower than its 3-year average PE of 56.3x.
  • The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.2% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-2.36%
Healthcare0.99%
Life Sciences-2.28%
Clinical Research and Equipment-2.28%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
WST West Pharmaceutical ServicesUS$330.344.1%
+US$919.8m		46.9%PE43x
MEDP Medpace HoldingsUS$475.073.6%
+US$467.8m		56.3%PE29.5x
RGEN RepligenUS$133.335.4%
+US$382.4m		1.5%PE146.3x
SHC Sotera HealthUS$16.395.3%
+US$233.8m		39.5%PE39.7x
TECH Bio-TechneUS$54.021.6%
+US$131.5m		4.8%PE77.2x

Latest News

DHR
US$180.79
Danaher
7D
-3.1%
1Y
-11.9%
AVTR
US$9.66
Avantor
7D
1.5%
1Y
-28.7%
WAT
US$359.74
Waters
7D
-4.4%
1Y
2.9%
TXG
US$29.05
10x Genomics
7D
-13.3%
1Y
174.6%
Seeking Alpha • Jun 10

10x Genomics: Temporary Pain, Long-Term Gain As Atera Rollout Approaches

Summary 10x Genomics is re-rated neutral after a 186% rally, with a $30 price target implying limited near-term upside. TXG's fundamentals improved: Q1 gross margin expanded to 70%, GAAP net loss narrowed by 61%, and operating expenses declined 15%. The Atera spatial platform offers significant long-term revenue potential, though near-term cannibalization and execution risks could cap upside. Balance sheet remains robust with $540 million cash and no debt, supporting future growth and product rollouts. Read the full article on Seeking Alpha
BRKR
US$55.18
Bruker
7D
-8.0%
1Y
38.4%
TMO
US$475.66
Thermo Fisher Scientific
7D
-1.3%
1Y
14.5%
Narrative Update • Jun 09

TMO: AI Tools And Proteomics Platforms Will Drive Future Upside

Thermo Fisher Scientific's updated fair value estimate has moved down from about $738 to $721 per share as analysts temper longer term revenue growth assumptions, partly reflecting recent price target cuts and more cautious views on organic growth momentum, even as they acknowledge that the company's margin profile and P/E remain supportive. Analyst Commentary Recent Street research paints a mixed picture for Thermo Fisher Scientific, with some analysts turning more cautious on near term organic growth while others highlight the stock as a core holding for exposure to life science tools.
WST
US$330.34
West Pharmaceutical Services
7D
4.1%
1Y
46.9%
A
US$129.55
Agilent Technologies
7D
-6.4%
1Y
8.9%
Narrative Update • Jun 06

A: AI Partnerships And New Diagnostics Offer Compelling Future Upside Potential

Analysts have adjusted their price target on Agilent Technologies slightly to $161.00. This reflects updated assumptions around discount rate, long term revenue growth, profit margins and future P/E expectations.
TECH
US$54.02
Bio-Techne
7D
1.6%
1Y
4.8%
MEDP
US$475.07
Medpace Holdings
7D
3.6%
1Y
56.3%
ADPT
US$18.73
Adaptive Biotechnologies
7D
3.6%
1Y
79.9%
RGEN
US$133.33
Repligen
7D
5.4%
1Y
1.5%
IQV
US$181.06
IQVIA Holdings
7D
-3.1%
1Y
13.8%
SHC
US$16.39
Sotera Health
7D
5.3%
1Y
39.5%
Narrative Update • Jun 04

SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside

Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.
MTD
US$1,141.25
Mettler-Toledo International
7D
-3.3%
1Y
-4.0%
Narrative Update • Jun 03

MTD: Automation And Emerging Markets Will Support EPS Upside Despite Geopolitical Risks

Analysts have trimmed their average price target for Mettler-Toledo International from about $1,344.50 to roughly $1,327.83. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations.
CRL
US$188.06
Charles River Laboratories International
7D
1.2%
1Y
23.8%
Narrative Update • Jun 03

CRL: Rich Multiple And Margin Pressure Will Likely Cap AI Upside

Analysts have lifted the fair value estimate for Charles River Laboratories International by about $6.81 per share to $154.56, citing a more supportive regulatory backdrop for cross-border biotech work and expectations that divesting lower margin operations could improve overall earnings quality. Analyst Commentary Recent research commentary on Charles River Laboratories International has leaned more constructive on the regulatory backdrop for cross-border biotech work and on the potential earnings mix shift from divesting lower margin activities.